1
|
Oqab Z, Kunadian V, Wood DA, Storey RF, Rao SV, Mehran R, Pinilla-Echeverri N, Mani T, Boone RH, Kassam S, Bossard M, Mansour S, Ball W, Sibbald M, Valettas N, Moreno R, Steg PG, Cairns JA, Mehta SR. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial. Circ Cardiovasc Interv 2023; 16:e012867. [PMID: 37725677 DOI: 10.1161/circinterventions.122.012867] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Accepted: 07/31/2023] [Indexed: 09/21/2023]
Abstract
BACKGROUND In the COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strategy of complete revascularization reduced the risk of major cardiovascular events compared with culprit-lesion-only percutaneous coronary intervention in patients presenting with ST-segment-elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Patients with diabetes have a worse prognosis following STEMI. We evaluated the consistency of the effects of complete revascularization in patients with and without diabetes. METHODS The COMPLETE trial randomized a strategy of complete revascularization, consisting of angiography-guided percutaneous coronary intervention of all suitable nonculprit lesions, versus a strategy of culprit-lesion-only percutaneous coronary intervention (guideline-directed medical therapy alone). In prespecified analyses, treatment effects were determined in patients with and without diabetes on the first coprimary outcome of cardiovascular death or new myocardial infarction and the second coprimary outcome of cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. Interaction P values were calculated to evaluate whether there was a differential treatment effect in patients with and without diabetes. RESULTS Of the 4041 patients enrolled in the COMPLETE trial, 787 patients (19.5%) had diabetes. The median HbA1c (glycated hemoglobin) was 7.7% in the diabetes group and 5.7% in the nondiabetes group. Complete revascularization consistently reduced the first coprimary outcome in patients with diabetes (hazard ratio, 0.87 [95% CI, 0.59-1.29]) and without diabetes (hazard ratio, 0.70 [95% CI, 0.55-0.90]), with no evidence of a differential treatment effect (interaction P=0.36). Similarly, for the second coprimary outcome, no differential treatment effect (interaction P=0.27) of complete revascularization was found in patients with diabetes (hazard ratio, 0.61 [95% CI, 0.43-0.87]) and without diabetes (hazard ratio, 0.48 [95% CI, 0.39-0.60]). CONCLUSIONS Among patients presenting with STEMI and multivessel disease, the benefit of complete revascularization over a culprit-lesion-only percutaneous coronary intervention strategy was consistent regardless of the presence or absence of diabetes.
Collapse
Affiliation(s)
- Zardasht Oqab
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Dalhousie University, Nova Scotia, Halifax, Canada (Z.O.)
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom (V.K.)
| | - David A Wood
- Centre for Cardiovascular Innovation, UBC Division of Cardiology, St Paul's and Vancouver General Hospital, Canada (D.A.W., R.H.B., J.A.C.)
| | - Robert F Storey
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom (R.F.S.)
| | - Sunil V Rao
- NYU Langone Health System, New York (S.V.R.)
| | - Roxana Mehran
- Zena A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (R.M.)
| | - Natalia Pinilla-Echeverri
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
| | - Thenmozhi Mani
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
| | - Robert H Boone
- Centre for Cardiovascular Innovation, UBC Division of Cardiology, St Paul's and Vancouver General Hospital, Canada (D.A.W., R.H.B., J.A.C.)
| | - Saleem Kassam
- Scarborough Health Network Centenary, Toronto, Ontario, Canada (S.K.)
| | | | - Samer Mansour
- Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada (S.M.)
| | - Warren Ball
- Peterborough Regional Health Centre, Toronto, Ontario, Canada (W.B.)
| | - Matthew Sibbald
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
| | - Nicholas Valettas
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
| | - Raul Moreno
- University Hospital La Paz, Madrid, Spain (R.M.)
| | | | - John A Cairns
- Centre for Cardiovascular Innovation, UBC Division of Cardiology, St Paul's and Vancouver General Hospital, Canada (D.A.W., R.H.B., J.A.C.)
| | - Shamir R Mehta
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.)
| |
Collapse
|
2
|
d'Entremont MA, Alrashidi S, Alansari O, Brochu B, Heenan L, Skuriat E, Tyrwhitt J, Raco M, Tsang M, Valettas N, Velianou JL, Sheth TN, Sibbald M, Mehta SR, Pinilla-Echeverri N, Schwalm JD, Natarajan MK, Kelly A, Akl E, Tawadros S, Camargo M, Faidi W, Bauer J, Moxham R, Nkurunziza J, Dutra G, Winter J, Jolly SS. Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial. EUROINTERVENTION 2023; 19:73-79. [PMID: 36876864 PMCID: PMC10174184 DOI: 10.4244/eij-d-22-01130] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Accepted: 02/08/2023] [Indexed: 03/07/2023]
Abstract
BACKGROUND Whether ultrasound (US)-guided femoral access compared to femoral access without US guidance decreases access site complications in patients receiving a vascular closure device (VCD) is unclear. AIMS We aimed to compare the safety of VCD in patients undergoing US-guided versus non-US-guided femoral arterial access for coronary procedures. METHODS We performed a prespecified subgroup analysis of the UNIVERSAL trial, a multicentre randomised controlled trial of 1:1 US-guided femoral access versus non-US-guided femoral access, stratified for planned VCD use, for coronary procedures on a background of fluoroscopic landmarking. The primary endpoint was a composite of major Bleeding Academic Research Consortium 2, 3 or 5 bleeding and vascular complications at 30 days. RESULTS Of 621 patients, 328 (52.8%) received a VCD (86% ANGIO-SEAL, 14% ProGlide). In patients who received a VCD, those randomised to US-guided femoral access compared to non-US-guided femoral access experienced a reduction in major bleeding or vascular complications (20/170 [11.8%] vs 37/158 [23.4%], odds ratio [OR] 0.44, 95% confidence interval [CI]: 0.23-0.82). In patients who did not receive a VCD, there was no difference between the US- and non-US-guided femoral access groups, respectively (20/141 [14.2%] vs 13/152 [8.6%], OR 1.76, 95% CI: 0.80-4.03; interaction p=0.004). CONCLUSIONS In patients receiving a VCD after coronary procedures, US-guided femoral access was associated with fewer bleeding and vascular complications compared to femoral access without US guidance. US guidance for femoral access may be particularly beneficial when VCD are used.
Collapse
Affiliation(s)
- Marc-André d'Entremont
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada
- Population Health Research Institute, Hamilton, ON, Canada
| | - Sulaiman Alrashidi
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Omar Alansari
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Bradley Brochu
- CK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, AB, Canada
| | - Laura Heenan
- Population Health Research Institute, Hamilton, ON, Canada
| | | | | | - Micheal Raco
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Micheal Tsang
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Nicholas Valettas
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - James L Velianou
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Tej N Sheth
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Matthew Sibbald
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Shamir R Mehta
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Natalia Pinilla-Echeverri
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Jon David Schwalm
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Madhu K Natarajan
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Andrew Kelly
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Elie Akl
- McGill University Faculty of Medicine and Health Sciences, Montreal, QC, Canada
| | | | | | - Walaa Faidi
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - John Bauer
- Hamilton Health Sciences, Hamilton, ON, Canada
| | | | - James Nkurunziza
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| | - Gustavo Dutra
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Jose Winter
- Clinica Alemana De Santiago, Universidad de Desarrollo, Santiago, Chile
| | - Sanjit S Jolly
- Population Health Research Institute, Hamilton, ON, Canada
- McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Niagara Health, St. Catharines, ON, Canada
| |
Collapse
|
3
|
Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, Schwalm JD, Sheth TN, Sibbald M, Tsang M, Valettas N, Velianou JL, Lee SF, Ferdous T, Nauman S, Nguyen H, McCready T, McQueen MJ. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EUROINTERVENTION 2022; 18:e888-e896. [PMID: 36349701 PMCID: PMC9743253 DOI: 10.4244/eij-d-22-00735] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 09/09/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND In patients with ST-segment elevation myocardial infarction (STEMI), early initiation of high-intensity statin therapy, regardless of low-density lipoprotein (LDL) cholesterol levels, is the standard of practice worldwide. Aims: We sought to determine the effect of a similar early initiation strategy, using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor added to the high-intensity statin, on LDL cholesterol in acute STEMI. METHODS In a randomised, double-blind trial we assigned 68 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) to early treatment with alirocumab 150 mg subcutaneously or to a matching sham control. The first injection was given before primary PCI regardless of the baseline LDL level, then at 2 and 4 weeks. The primary outcome was the percent reduction in direct LDL cholesterol up to 6 weeks, analysed using a linear mixed model. Results: High-intensity statin use was 97% and 100% in the alirocumab and sham-control groups, respectively. At a median of 45 days, the primary outcome of LDL cholesterol decreased by 72.9% with alirocumab (2.97 mmol/L to 0.75 mmol/L) versus 48.1% with the sham control (2.87 mmol/L to 1.30 mmol/L), for a mean between-group difference of -22.3% (p<0.001). More patients achieved the European Society of Cardiology/European Atherosclerosis Society dyslipidaemia guideline target of LDL ≤1.4 mmol/L in the alirocumab group (92.1% vs 56.7%; p<0.001). Within the first 24 hours, LDL declined slightly more rapidly in the alirocumab group than in the sham-control group (-0.01 mmol/L/hour; p=0.03) with similar between-group mean values. Conclusions: In this randomised trial of routine early initiation of PCSK9 inhibitors in patients undergoing primary PCI for STEMI, alirocumab reduced LDL cholesterol by 22% compared with sham control on a background of high-intensity statin therapy. A large trial is needed to determine if this simplified approach followed by long-term therapy improves cardiovascular outcomes in patients with acute STEMI. (ClinicalTrials.gov: NCT03718286).
Collapse
Affiliation(s)
- Shamir R Mehta
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Guillaume Pare
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - Eva M Lonn
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Sanjit S Jolly
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Madhu K Natarajan
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Natalia Pinilla-Echeverri
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Jon-David Schwalm
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Tej N Sheth
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Matthew Sibbald
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Michael Tsang
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Nicholas Valettas
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - James L Velianou
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
| | - Shun Fu Lee
- Population Health Research Institute, Hamilton, ON, Canada
| | - Tahsin Ferdous
- Population Health Research Institute, Hamilton, ON, Canada
| | | | - Helen Nguyen
- Population Health Research Institute, Hamilton, ON, Canada
| | - Tara McCready
- Population Health Research Institute, Hamilton, ON, Canada
| | - Matthew J McQueen
- Population Health Research Institute, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Hamilton Health Sciences, Hamilton, ON, Canada
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
4
|
Jolly SS, AlRashidi S, d’Entremont MA, Alansari O, Brochu B, Heenan L, Skuriat E, Tyrwhitt J, Raco M, Tsang M, Valettas N, Velianou JL, Sheth T, Sibbald M, Mehta SR, Pinilla-Echeverri N, Schwalm JD, Natarajan MK, Kelly A, Akl E, Tawadros S, Camargo M, Faidi W, Bauer J, Moxham R, Nkurunziza J, Dutra G, Winter J. Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial. JAMA Cardiol 2022; 7:1110-1118. [PMID: 36116089 PMCID: PMC9483833 DOI: 10.1001/jamacardio.2022.3399] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 08/19/2022] [Indexed: 12/15/2022]
Abstract
Importance A significant limitation of femoral artery access for cardiac interventions is the increased risk of vascular complications and bleeding compared with radial access. Strategies to make femoral access safer are needed. Objective To determine whether routinely using ultrasonography guidance for femoral arterial access for coronary angiography/intervention reduces bleeding or vascular complications. Design, Setting, and Participants The Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures (UNIVERSAL) randomized clinical trial is a multicenter, prospective, open-label trial of ultrasonography-guided femoral access vs no ultrasonography for coronary angiography or intervention with planned femoral access. Patients were randomized from June 26, 2018, to April 26, 2022. Patients with ST-elevation myocardial infarction were not eligible. Interventions Ultrasonography guidance vs no ultrasonography guidance for femoral arterial access on a background of fluoroscopic landmarking. Main Outcomes and Measures The primary composite outcome is the composite of major bleeding based on the Bleeding Academic Research Consortium 2, 3, or 5 criteria or major vascular complications within 30 days. Results A total of 621 patients were randomized at 2 centers in Canada (mean [SD] age, 71 [10.24] years; 158 [25.4%] female). The primary outcome occurred in 40 of 311 patients (12.9%) in the ultrasonography group vs 50 of 310 patients (16.1%) without ultrasonography (odds ratio, 0.77 [95% CI, 0.49-1.20]; P = .25). The rates of Bleeding Academic Research Consortium 2, 3, or 5 bleeding were 10.0% (31 of 311) vs 10.7% (33 of 310) (odds ratio, 0.93 [95% CI, 0.55-1.56]; P = .78). The rates of major vascular complications were 6.4% (20 of 311) vs 9.4% (29 of 310) (odds ratio, 0.67 [95% CI, 0.37-1.20]; P = .18). Ultrasonography improved first-pass success (277 of 311 [86.6%] vs 222 of 310 [70.0%]; odds ratio, 2.76 [95% CI, 1.85-4.12]; P < .001) and reduced the number of arterial puncture attempts (mean [SD], 1.2 [0.5] vs 1.4 [0.8]; mean difference, -0.26 [95% CI, -0.37 to -0.16]; P < .001) and venipuncture (10 of 311 [3.1%] vs 37 of 310 [11.7%]; odds ratio, 0.24 [95% CI, 0.12-0.50]; P < .001) with similar times to access (mean [SD], 114 [185] vs 129 [206] seconds; mean difference, -15.1 [95% CI, -45.9 to 15.8]; P = .34). All prerandomization prespecified subgroups were consistent with the overall finding. Conclusions and Relevance In this randomized clinical trial, use of ultrasonography for femoral access did not reduce bleeding or vascular complications. However, ultrasonography did reduce the risk of venipuncture and number of attempts. Larger trials may be required to demonstrate additional potential benefits of ultrasonography-guided access. Trial Registration ClinicalTrials.gov Identifier: NCT03537118.
Collapse
Affiliation(s)
- Sanjit S. Jolly
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Sulaiman AlRashidi
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Marc-André d’Entremont
- Population Health Research Institute, Hamilton, Ontario, Canada
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
| | - Omar Alansari
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Bradley Brochu
- CK Hui Heart Centre, Royal Alexandra Hospital Edmonton, Edmonton, Alberta, Canada
| | - Laura Heenan
- Population Health Research Institute, Hamilton, Ontario, Canada
| | | | | | - Michael Raco
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Michael Tsang
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Nicholas Valettas
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - James L. Velianou
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Tej Sheth
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Matthew Sibbald
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Shamir R. Mehta
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Natalia Pinilla-Echeverri
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Jon David Schwalm
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Madhu K. Natarajan
- Population Health Research Institute, Hamilton, Ontario, Canada
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Andrew Kelly
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Elie Akl
- McGill University Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada
| | | | | | - Walaa Faidi
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - John Bauer
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | | | - James Nkurunziza
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
- Niagara Health, St Catherines, Ontario, Canada
| | - Gustavo Dutra
- McMaster University, Hamilton, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Jose Winter
- Departamento de enfermedades cardiovasculares, Clínica Alemana De Santiago, Universidad del Desarrollo, Chile
| |
Collapse
|
5
|
Oqab Z, Kunadian V, Wood D, Rao S, Mehran R, Pinilla N, Storey R, Boone R, Sibbald M, Valettas N, Moreno R, Steg PG, Cairns J, Mehta S. TCT-36 Complete Revascularization Versus Culprit Lesion–Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial. J Am Coll Cardiol 2022. [DOI: 10.1016/j.jacc.2022.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Alrashidi S, d’Entremont MA, Alansari O, Winter J, Brochu B, Heenan L, Skuriat E, Tyrwhitt J, Raco M, Tsang MB, Valettas N, Velianou J, Sheth T, Sibbald M, Mehta SR, Pinilla-Echeverri N, Schwalm JD, Natarajan MK, Kelly A, Akl E, Tawadros S, Camargo M, Faidi W, Dutra G, Jolly SS. Design and Rationale of Routine Ultrasou Nd Gu Idance for Vascular Acc Ess fo R Cardiac Procedure s: A Randomized Tria L (UNIVERSAL). CJC Open 2022; 4:1074-1080. [PMID: 36562014 PMCID: PMC9764117 DOI: 10.1016/j.cjco.2022.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 08/22/2022] [Indexed: 12/25/2022] Open
Abstract
Background A significant limitation of femoral artery access for cardiac interventions is the increased risk of vascular complications and bleeding compared to radial access. Ultrasound (US)-guided femoral access may reduce major vascular complications and bleeding. We aim to determine whether routinely using US guidance for femoral arterial access for coronary angiography or intervention will reduce Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding or major vascular complications. Methods The Ultrasound Guidance for Vascular Access for Cardiac Procedures: A Randomized Trial (UNIVERSAL) is a multicentre, prospective, open-label, randomized trial with blinded outcomes assessment. Patients undergoing coronary angiography with or without intervention via a femoral approach with fluoroscopic guidance will be randomized 1:1 to US-guided femoral access, compared to no US. The primary outcome is the composite of major bleeding based on the BARC 2, 3, or 5 criteria or major vascular complications within 30 days. The trial is designed to have 80% power and a 2-sided alpha level of 5% to detect a 50% relative risk reduction for the primary outcome based on a control event rate of 14%. Results We completed enrollment on April 29, 2022, with 621 randomized patients. The patients had a mean age of 71 years (25.4% female), with a high rate of comorbidities, as follows: 45% had a prior percutaneous coronary intervention; 57% had previous coronary artery bypass surgery; and 18% had peripheral vascular disease. Conclusions The UNIVERSAL trial will be one of the largest randomized trials of US-guided femoral access and has the potential to change guidelines and increase US uptake for coronary procedures worldwide.
Collapse
Affiliation(s)
- Sulaiman Alrashidi
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Marc-André d’Entremont
- Population Health Research Institute, Hamilton, Ontario, Canada,Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
| | - Omar Alansari
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Jose Winter
- Clinica Alemana de Santiago, Santiago, Chile
| | - Bradley Brochu
- CK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, Alberta, Canada
| | - Laura Heenan
- Population Health Research Institute, Hamilton, Ontario, Canada
| | | | | | - Michael Raco
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Michael B. Tsang
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Nicholas Valettas
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - James Velianou
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Tej Sheth
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada
| | - Matthew Sibbald
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Shamir R. Mehta
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada
| | - Natalia Pinilla-Echeverri
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada
| | - Jon David Schwalm
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada
| | - Madhu K. Natarajan
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada
| | - Andrew Kelly
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada
| | - Elie Akl
- McGill University Health Centre, Montreal, Quebec, Canada
| | | | | | - Walaa Faidi
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Gustavo Dutra
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Sanjit S. Jolly
- McMaster University, Hamilton, Ontario, Canada,Hamilton Health Sciences, Hamilton, Ontario, Canada,Niagara Health, St. Catharines, Ontario, Canada,Population Health Research Institute, Hamilton, Ontario, Canada,Corresponding author: Dr Sanjit S. Jolly, Population Health Research Institute, Hamilton General Hospital, 237 Barton St. East, Hamilton, Ontario L8L 2X2, Canada. Tel.: +1-905-521-2100 ext. 40309.
| |
Collapse
|
7
|
d'Entremont MA, Couture ÉL, Connelly K, Walling A, Jolly SS, Valettas N, Tsang MB, Mampuya W, Poirier P, Huynh T. Management of the master endurance athlete with stable coronary artery disease. Can J Cardiol 2022; 38:1450-1453. [PMID: 35489669 DOI: 10.1016/j.cjca.2022.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 04/05/2022] [Accepted: 04/17/2022] [Indexed: 11/02/2022] Open
Abstract
Master endurance athletes are individuals > 35 years of age who either train for or participate in competitions. Considering the potential burden of coronary artery disease in this population, clinicians should be aware of the inherent dangers of exercise. A tailored approach with shared decision-making, balancing risks and benefits of exercise, is recommended to ensure safe exercise in these individuals.
Collapse
Affiliation(s)
| | - Étienne L Couture
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke (QC), Canada
| | - Kim Connelly
- Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (ON), Canada; Department of Physiology, University of Toronto, Toronto (ON), Canada; Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto (ON), Canada
| | - Ann Walling
- Sir Mortimer B. Davis Jewish General Hospital, Montreal (QC), Canada
| | - Sanjit S Jolly
- McGill Health University Center, Montreal (QC), Canada; Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Nicholas Valettas
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Micheal B Tsang
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton Health Sciences, Hamilton (ON), Canada
| | - Warner Mampuya
- Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke (QC), Canada
| | - Paul Poirier
- Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec (QC), Canada
| | - Thao Huynh
- McGill Health University Center, Montreal (QC), Canada.
| |
Collapse
|
8
|
Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S, Schwalm JD, Velianou JL, Valettas N, Sibbald M, Rodés-Cabau J, Ducas J, Cohen EA, Bagai A, Rinfret S, Newby DE, Feldman L, Laster SB, Lang IM, Mills JD, Cairns JA, Mehta SR. Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. J Am Coll Cardiol 2020; 76:1277-1286. [PMID: 32912441 DOI: 10.1016/j.jacc.2020.07.034] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Accepted: 07/10/2020] [Indexed: 11/20/2022]
Abstract
BACKGROUND In the COMPLETE (Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI) trial, angiography-guided percutaneous coronary intervention (PCI) of nonculprit lesions with the aim of complete revascularization reduced major cardiovascular (CV) events in patients with ST-segment elevation myocardial infarction (MI) and multivessel coronary artery disease. OBJECTIVES The purpose of this study was to determine the effect of nonculprit-lesion stenosis severity measured by quantitative coronary angiography (QCA) on the benefit of complete revascularization. METHODS Among 4,041 patients randomized in the COMPLETE trial, nonculprit lesion stenosis severity was measured using QCA in the angiographic core laboratory in 3,851 patients with 5,355 nonculprit lesions. In pre-specified analyses, the treatment effect in patients with QCA stenosis ≥60% versus <60% on the first coprimary outcome of CV death or new MI and the second co-primary outcome of CV death, new MI, or ischemia-driven revascularization was determined. RESULTS The first coprimary outcome was reduced with complete revascularization in the 2,479 patients with QCA stenosis ≥60% (2.5%/year vs. 4.2%/year; hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.47 to 0.79), but not in the 1,372 patients with QCA stenosis <60% (3.0%/year vs. 2.9%/year; HR: 1.04; 95% CI: 0.72 to 1.50; interaction p = 0.02). The second coprimary outcome was reduced in patients with QCA stenosis ≥60% (2.9%/year vs. 6.9%/year; HR: 0.43; 95% CI: 0.34 to 0.54) to a greater extent than patients with QCA stenosis <60% (3.3%/year vs. 5.2%/year; HR: 0.65; 95% CI: 0.47 to 0.89; interaction p = 0.04). CONCLUSIONS Among patients with ST-segment elevation MI and multivessel coronary artery disease, complete revascularization reduced major CV outcomes to a greater extent in patients with stenosis severity of ≥60% compared with <60%, as determined by quantitative coronary angiography.
Collapse
Affiliation(s)
- Tej Sheth
- Population Health Research Institute, Hamilton, Ontario, Canada; McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada. https://twitter.com/PHRIresearch
| | - Natalia Pinilla-Echeverri
- Population Health Research Institute, Hamilton, Ontario, Canada; McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | | | - Jia Wang
- Population Health Research Institute, Hamilton, Ontario, Canada; McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - David A Wood
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Robert F Storey
- Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
| | - Roxana Mehran
- Zena A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Kevin R Bainey
- University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
| | - Matthias Bossard
- Cardiology Division, Heart Center, Luzerner Kantonsspital, Luzern, Switzerland
| | | | - Jon-David Schwalm
- Population Health Research Institute, Hamilton, Ontario, Canada; McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - James L Velianou
- McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Nicholas Valettas
- McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Matthew Sibbald
- McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - Josep Rodés-Cabau
- Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - John Ducas
- University of Manitoba, Winnipeg, Manitoba, Canada
| | - Eric A Cohen
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Akshay Bagai
- Terrence Donnelly Heart Centre, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | | | - Laurent Feldman
- Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Steven B Laster
- St. Luke's Mid-America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Irene M Lang
- Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Joseph D Mills
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | - John A Cairns
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Shamir R Mehta
- Population Health Research Institute, Hamilton, Ontario, Canada; McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada. https://twitter.com/PHRIresearch
| |
Collapse
|
9
|
Tsang MB, Schwalm JD, Gandhi S, Sibbald MG, Gafni A, Mercuri M, Salehian O, Lamy A, Pericak D, Jolly S, Sheth T, Ainsworth C, Velianou J, Valettas N, Mehta S, Pinilla N, Yanagawa B, Zhang L, Chu V, Parry D, Whitlock R, Dyub A, Cybulsky I, Semelhago L, Ioannou K, Hameed A, Wright D, Mulji A, Darvish-Kazem S, Gupta N, Alshatti A, Natarajan MK. Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease. JAMA Netw Open 2020; 3:e2012749. [PMID: 32777060 PMCID: PMC7417969 DOI: 10.1001/jamanetworkopen.2020.12749] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
IMPORTANCE Although the heart team approach is recommended in revascularization guidelines, the frequency with which heart team decisions differ from those of the original treating interventional cardiologist is unknown. OBJECTIVE To examine the difference in decisions between the heart team and the original treating interventional cardiologist for the treatment of patients with multivessel coronary artery disease. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, 245 consecutive patients with multivessel coronary artery disease were recruited from 1 high-volume tertiary care referral center (185 patients were enrolled through a screening process, and 60 patients were retrospectively enrolled from the center's database). A total of 237 patients were included in the final virtual heart team analysis. Treatment decisions (which comprised coronary artery bypass grafting, percutaneous coronary intervention, and medication therapy) were made by the original treating interventional cardiologists between March 15, 2012, and October 20, 2014. These decisions were then compared with pooled-majority treatment decisions made by 8 blinded heart teams using structured online case presentations between October 1, 2017, and October 15, 2018. The randomized members of the heart teams comprised experts from 3 domains, with each team containing 1 noninvasive cardiologist, 1 interventional cardiologist, and 1 cardiovascular surgeon. Cases in which all 3 of the heart team members disagreed and cases in which procedural discordance occurred (eg, 2 members chose coronary artery bypass grafting and 1 member chose percutaneous coronary intervention) were discussed in a face-to-face heart team review in October 2018 to obtain pooled-majority decisions. Data were analyzed from May 6, 2019, to April 22, 2020. MAIN OUTCOMES AND MEASURES The Cohen κ coefficient between the treatment recommendation from the heart team and the treatment recommendation from the original treating interventional cardiologist. RESULTS Among 234 of 237 patients (98.7%) in the analysis for whom complete data were available, the mean (SD) age was 67.8 (10.9) years; 176 patients (75.2%) were male, and 191 patients (81.4%) had stenosis in 3 epicardial coronary vessels. A total of 71 differences (30.3%; 95% CI, 24.5%-36.7%) in treatment decisions between the heart team and the original treating interventional cardiologist occurred, with a Cohen κ of 0.478 (95% CI, 0.336-0.540; P = .006). The heart team decision was more frequently unanimous when it was concordant with the decision of the original treating interventional cardiologist (109 of 163 cases [66.9%]) compared with when it was discordant (28 of 71 cases [39.4%]; P < .001). When the heart team agreed with the original treatment decision, there was more agreement between the heart team interventional cardiologist and the original treating interventional cardiologist (138 of 163 cases [84.7%]) compared with when the heart team disagreed with the original treatment decision (14 of 71 cases [19.7%]); P < .001). Those with an original treatment of coronary artery bypass grafting, percutaneous coronary intervention, and medication therapy, 32 of 148 patients [22.3%], 32 of 71 patients [45.1%], and 6 of 15 patients [40.0%], respectively, received a different treatment recommendation from the heart team than the original treating interventional cardiologist; the difference across the 3 groups was statistically significant (P = .002). CONCLUSIONS AND RELEVANCE The heart team's recommended treatment for patients with multivessel coronary artery disease differed from that of the original treating interventional cardiologist in up to 30% of cases. This subset of cases was associated with a lower frequency of unanimous decisions within the heart team and less concordance between the interventional cardiologists; discordance was more frequent when percutaneous coronary intervention or medication therapy were considered. Further research is needed to evaluate whether heart team decisions are associated with improvements in outcomes and, if so, how to identify patients for whom the heart team approach would be beneficial.
Collapse
Affiliation(s)
- Michael B. Tsang
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - J. D. Schwalm
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Sumeet Gandhi
- Division of Cardiology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Trillium Health Partners, Mississauga, Ontario, Canada
| | - Matthew G. Sibbald
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Amiram Gafni
- Center for Health Economics and Policy Analysis, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Mathew Mercuri
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Omid Salehian
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Andre Lamy
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Dan Pericak
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Sanjit Jolly
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Tej Sheth
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Craig Ainsworth
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - James Velianou
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Nicholas Valettas
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Shamir Mehta
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Natalia Pinilla
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Bobby Yanagawa
- Division of Cardiovascular Surgery, St Michael’s Hospital, Toronto, Ontario, Canada
- Division of Cardiac Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Li Zhang
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Victor Chu
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Dominic Parry
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
- Dunedin Hospital, Otago, New Zealand
| | - Richard Whitlock
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Adel Dyub
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Irene Cybulsky
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Lloyd Semelhago
- Division of Cardiovascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Kostas Ioannou
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada
| | - Adnan Hameed
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Douglas Wright
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Amin Mulji
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Saeed Darvish-Kazem
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Brampton Civic Hospital, William Osler Health System, Brampton, Ontario, Canada
| | - Nandini Gupta
- Division of Cardiology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Ahmed Alshatti
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Madhu K. Natarajan
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
10
|
Allahwala UK, Jolly SS, Džavík V, Cairns JA, Kedev S, Balasubramanian K, Stankovic G, Moreno R, Valettas N, Bertrand O, Lavi S, Velianou JL, Sheth T, Meeks B, Brilakis ES, Bhindi R. The Presence of a CTO in a Non-Infarct-Related Artery During a STEMI Treated With Contemporary Primary PCI Is Associated With Increased Rates of Early and Late Cardiovascular Morbidity and Mortality: The CTO-TOTAL Substudy. JACC Cardiovasc Interv 2019; 11:709-711. [PMID: 29622151 DOI: 10.1016/j.jcin.2017.12.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 11/16/2017] [Accepted: 12/05/2017] [Indexed: 12/22/2022]
|
11
|
Bossard M, Lavi S, Rao SV, Cohen DJ, Cantor WJ, Bainey KR, Valettas N, Jolly SS, Mehta SR. Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns. Catheter Cardiovasc Interv 2018; 92:854-859. [DOI: 10.1002/ccd.27530] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 12/08/2017] [Accepted: 01/15/2018] [Indexed: 01/29/2023]
Affiliation(s)
- Matthias Bossard
- Division of Cardiology; Hamilton General Hospital, Hamilton Health Sciences, McMaster University; Hamilton Ontario Canada
- Population Health Research Institute, McMaster University Hamilton Health Sciences; Hamilton Ontario Canada
| | - Shahar Lavi
- Division of Cardiology; London Health Sciences Centre, Western University; London Ontario Canada
| | - Sunil V. Rao
- Duke Clinical Research Institute; Durham North Carolina
- Division of Cardiology, Department of Medicine; Duke University School of Medicine; Durham North Carolina
| | - David J. Cohen
- Saint Luke's Mid America Heart Institute; Kansas City Missouri
| | - Warren J. Cantor
- York Clinical Cardiology; Southlake Regional Health Centre; Vaughan Ontario
| | - Kevin R. Bainey
- Division of Cardiology; Mazankowski Alberta Heart Institute, University of Alberta; Edmonton Alberta Canada
| | - Nicholas Valettas
- Division of Cardiology; Hamilton General Hospital, Hamilton Health Sciences, McMaster University; Hamilton Ontario Canada
| | - Sanjit S. Jolly
- Division of Cardiology; Hamilton General Hospital, Hamilton Health Sciences, McMaster University; Hamilton Ontario Canada
- Population Health Research Institute, McMaster University Hamilton Health Sciences; Hamilton Ontario Canada
| | - Shamir R. Mehta
- Division of Cardiology; Hamilton General Hospital, Hamilton Health Sciences, McMaster University; Hamilton Ontario Canada
- Population Health Research Institute, McMaster University Hamilton Health Sciences; Hamilton Ontario Canada
| |
Collapse
|
12
|
Menon SD, Whitlock R, Valettas N, Healey JS. Unconventional warfare: Successful ablation of ventricular tachycardia by direct ventricular puncture in a patient with double mechanical heart valves. HeartRhythm Case Rep 2018; 3:599-603. [PMID: 29296585 PMCID: PMC5741813 DOI: 10.1016/j.hrcr.2017.10.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
13
|
|
14
|
Alazzoni A, Gordon CL, Syed J, Natarajan MK, Rokoss M, Schwalm JD, Mehta SR, Sheth T, Valettas N, Velianou J, Pandie S, Al Khdair D, Tsang M, Meeks B, Colbran K, Waller E, Fu Lee S, Marsden T, Jolly SS. Randomized Controlled Trial of Radiation Protection With a Patient Lead Shield and a Novel, Nonlead Surgical Cap for Operators Performing Coronary Angiography or Intervention. Circ Cardiovasc Interv 2015; 8:e002384. [DOI: 10.1161/circinterventions.115.002384] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Ashraf Alazzoni
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Chris L. Gordon
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Jaffer Syed
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Madhu K. Natarajan
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Michael Rokoss
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Jon-David Schwalm
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Shamir R. Mehta
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Tej Sheth
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Nicholas Valettas
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - James Velianou
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Shaheen Pandie
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Darar Al Khdair
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Michael Tsang
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Brandi Meeks
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Kiersten Colbran
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Ed Waller
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Shun Fu Lee
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Tamara Marsden
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| | - Sanjit S. Jolly
- From the Department of Medicine and the Population Health Research Institute (PHRI), McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (A.A., C.L.G., J.S., M.K.N., M.R., J.-D.S., S.R.M., T.S., N.V., J.V., S.P., D.A.K., M.T., B.M., K.C., S.F.L., T.M., S.S.J.); and Faculty of Energy Systems and Nuclear Science, Institute of Technology, University of Ontario, Oshawa, Ontario, Canada (E.W.)
| |
Collapse
|
15
|
Jolly SS, Cairns JA, Yusuf S, Meeks B, Gao P, Hart RG, Kedev S, Stankovic G, Moreno R, Horak D, Kassam S, Rokoss MJ, Leung RCM, El-Omar M, Romppanen HO, Alazzoni A, Alak A, Fung A, Alexopoulos D, Schwalm JD, Valettas N, Džavík V. Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. Eur Heart J 2015; 36:2364-72. [PMID: 26129947 DOI: 10.1093/eurheartj/ehv296] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 06/08/2015] [Indexed: 11/14/2022] Open
Abstract
AIMS TOTAL (N = 10 732), a randomized trial of routine manual thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction, showed no difference in the primary efficacy outcome but a significant increase in stroke. We sought to understand these findings. METHODS AND RESULTS A detailed analysis of stroke timing, stroke severity, and stroke subtype was performed. Strokes were adjudicated by neurologists blinded to treatment assignment. Stroke within 30 days, the primary safety outcome, was increased [33 (0.7%) vs. 16 (0.3%), hazard ratio (HR) 2.06; 95% confidence interval (CI) 1.13-3.75]. The difference in stroke was apparent within 48 h [15 (0.3%) vs. 5 (0.1%), HR 3.00; 95% CI 1.09-8.25]. There was an increase in strokes within 180 days with minor or no disability (Rankin 0-2) [18 (0.4%) vs. 13 (0.3%) HR 1.38; 95% CI 0.68-2.82] and in strokes with major disability or fatal (Rankin 3-6) [35 (0.7%) vs. 13 (0.3%), HR 2.69; 95% CI 1.42-5.08]. Most of the absolute difference was due to an increase in ischaemic strokes within 180 days [37 (0.7%) vs. 21 (0.4%), HR 1.71; 95% CI 1.03-3.00], but there was also an increase in haemorrhagic strokes [10 (0.2%) vs. 2 (0.04%), HR 4.98; 95% CI 1.09-22.7]. Patients that had a stroke had a mortality of 30.8% within 180 days vs. 3.4% without a stroke (P < 0.001). A meta-analysis of randomized trials (N = 21 173) showed an increase in risk of stroke (odds ratio 1.59; 95% CI 1.11-2.27) but a trend towards reduction in mortality odds ratio (odds ratio 0.87; 95% CI 0.76-1.00). CONCLUSION Thrombectomy was associated with a significant increase in stroke. Based on these findings, future trials must carefully collect stroke to determine safety in addition to efficacy.
Collapse
Affiliation(s)
- Sanjit S Jolly
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - John A Cairns
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Salim Yusuf
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Brandi Meeks
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Peggy Gao
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Robert G Hart
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Sasko Kedev
- University Clinic of Cardiology, Sts. Cyril and Methodius University, Skopje, Macedonia
| | - Goran Stankovic
- Clinical Center of Serbia, Department of Cardiology, Medical Faculty, University of Belgrade, Belgrade, Serbia
| | | | - David Horak
- Krajská Nemocnice Liberec, Liberec, Czech Republic
| | | | - Michael J Rokoss
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | | | - Magdi El-Omar
- Central Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | | | - Ashraf Alazzoni
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Aiman Alak
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Anthony Fung
- Division of Cardiology, Vancouver General Hospital/University of British Columbia, Vancouver, BC, Canada
| | | | - John D Schwalm
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Nicholas Valettas
- The Population Health Research Institute, Hamilton Health Sciences, McMaster University, Rm. C3-118, DBCVSRI Building, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON, L8L 2X2, Canada
| | - Vladimír Džavík
- Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
| | | |
Collapse
|
16
|
Alazzoni A, Al Khdair D, Casanova A, Meeks B, Rokoss M, Schwalm JD, Shaheen P, Sheth T, Tsang MB, Valettas N, Waller E, Natarajan MK, Mehta S, Jolly S. TCT- 145 RADIATION PROTECT: A randomized trial to assess the effectiveness of a novel pelvic lead shield and a novel, non-lead surgical cap to reduce operator radiation exposure during coronary angiography or intervention. J Am Coll Cardiol 2014. [DOI: 10.1016/j.jacc.2014.07.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Rao R, Devereaux P, Graham M, Natarajan M, Valettas N, Sheth T. 244 Angiographic features of perioperative myocardial infarction (POMI). Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
18
|
Paikin J, Eikelboom J, Brons S, Rokoss M, Valettas N, Velianou J, Natarajan M, Mehta S. 331 Distribution of response to clopidogrel therapy using vasodilator stimulated phosphoprotein assay in patients undergoing primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Can J Cardiol 2011. [DOI: 10.1016/j.cjca.2011.07.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Mercuri M, Mehta S, Xie C, Valettas N, Velianou JL, Natarajan MK. Radial Artery Access as a Predictor of Increased Radiation Exposure During a Diagnostic Cardiac Catheterization Procedure. JACC Cardiovasc Interv 2011; 4:347-52. [DOI: 10.1016/j.jcin.2010.11.011] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Revised: 11/17/2010] [Accepted: 11/26/2010] [Indexed: 10/18/2022]
|
20
|
Mercuri M, Xie C, Levy M, Valettas N, Natarajan MK. Predictors of increased radiation dose during percutaneous coronary intervention. Am J Cardiol 2009; 104:1241-4. [PMID: 19840569 DOI: 10.1016/j.amjcard.2009.06.037] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2009] [Revised: 06/11/2009] [Accepted: 06/11/2009] [Indexed: 11/18/2022]
Abstract
Radiation-induced injury is a potential unintended outcome of fluoroscopy-supported cardiology procedures (e.g., percutaneous coronary intervention [PCI]). The injury might be deterministic in nature. Air kerma (AK) is considered an indicator of skin dose, and thus, an indicator for deterministic effects. Few studies have investigated the factors that contribute to an increased radiation dose, and none have used AK as a dependent variable. We studied the registry data of 967 consecutive patients (derivation model) undergoing ad hoc PCI. Linear and multiple regression analyses were performed to investigate which clinical, technical, and anatomic factors were associated with an increased AK. Multiple regression analyses were performed on an additional sample of 1,082 consecutive patients (validation model) to confirm the results. The variables found significant (multiple regression analyses) were radial access (mean increase in AK 253 mGy, 95% confidence interval [CI] 104 to 418, p = 0.0006), number of lesions treated (547 mGy, 95% CI 332 to 789, p < 0.0001), Type C lesions (132 mGy, 95% CI, 26 to 246, p = 0.014), bifurcation lesions (280 mGy, 95% CI 104 to 477, p = 0.0013), and chronic total occlusions (453 mGy, 95% CI 76 to 923, p = 0.016). The validation model (n = 1,082) confirmed all but type C lesions (p = 0.065). In conclusion, the present study has described factors that might contribute to an increased AK during PCI. In revealing a priori known factors associated with an increased radiation dose during PCI, physicians and patients might be more able to evaluate the risks and benefits of such a procedure.
Collapse
Affiliation(s)
- Mathew Mercuri
- Heart Investigation Unit, Hamilton Health Sciences, Hamilton, Ontario, Canada.
| | | | | | | | | |
Collapse
|
21
|
Ravandi A, Sun JCJ, Lamy A, Valettas N. Images in cardiovascular medicine. Fluoroscopy of acutely thrombosed aortic valve. Circulation 2008; 118:e705. [PMID: 19029472 DOI: 10.1161/circulationaha.108.786228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- A Ravandi
- Division of Cardiology, McMaster University, Hamilton General Hospital, Hamilton, ON, Canada.
| | | | | | | |
Collapse
|
22
|
Valettas N. Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI? Nat Clin Pract Cardiovasc Med 2005; 2:500-1. [PMID: 16186842 DOI: 10.1038/ncpcardio0293] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2005] [Accepted: 07/07/2005] [Indexed: 12/31/2022]
|
23
|
Valettas N, Gorman JH, Gorman RC. Pathophysiology and Percutaneous Coronary Sinus Repair of Mitral Regurgitation. Interv Cardiol 2005. [DOI: 10.1385/1-59259-898-6:049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
24
|
Affiliation(s)
- Nicholas Valettas
- Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, USA
| | | |
Collapse
|
25
|
Valettas N, Rho R, Beshai J, Lloyd CT, Ross HM, Kocovic D, Herrmann HC. Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheter Cardiovasc Interv 2003; 58:189-93. [PMID: 12552542 DOI: 10.1002/ccd.10412] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Alcohol septal ablation is a novel catheter-based technique for the treatment of obstructive hypertrophic cardiomyopathy. Complete heart block complicates the procedure in 7%-30% of cases and necessitates the prophylactic insertion of a temporary pacing wire in all patients who do not have a permanent pacemaker. We describe a case of alcohol septal ablation complicated by complete heart block and failure to capture by both a permanent pacemaker and an implantable cardioverter defibrillator (ICFD) with pacing capabilities.
Collapse
Affiliation(s)
- Nicholas Valettas
- Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Woo YJ, Grand T, Valettas N. Off-pump coronary artery bypass grafting attenuates postoperative bleeding associated with preoperative clopidogrel administration. Heart Surg Forum 2003; 6:282-5. [PMID: 14721793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
BACKGROUND Clopidogrel is being increasingly administered as primary therapy for acute coronary syndromes and prior to planned percutaneous coronary intervention (PCI). In these settings, surgical revascularization results in signifi- cantly increased postoperative bleeding, transfusion, and reexploration. Off-pump coronary artery bypass grafting (OPCAB) may decrease the extent of postoperative bleeding in patients exposed to clopidogrel. METHODS The cases of 78 consecutive patients undergoing OPCAB by a single surgeon were retrospectively analyzed, and the patients were divided into 2 groups, those with immediately preoperative clopidogrel exposure (clopidogrel OPCAB, n = 15) and those without (control OPCAB, n = 63). Multiple perioperative parameters were statistically compared. The clopidogrel OPCAB group also was compared with a group of previously described on-pump coronary bypass patients who made up a historical control group (n = 59). RESULTS Postoperative bleeding, transfusion requirements, reexploration rates, duration of mechanical ventilation, and length of stay were markedly less for clopidogrel OPCAB patients than for historical controls and were statistically equivalent to those of control OPCAB patients. CONCLUSION Among these 15 OPCAB patients with immediately preoperative administration of clopidogrel and aspirin, outcome was improved compared with published results for on-pump coronary bypass patients and was equivalent to results among OPCAB patients not exposed to clopidogrel. Published, recommended approaches to clopidogrel administration, such as avoidance of pre-PCI clopidogrel, delay of surgery, and platelet transfusion do not appear to be necessary with OPCAB.
Collapse
Affiliation(s)
- Y Joseph Woo
- Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
| | | | | |
Collapse
|
27
|
Herrmann HC, Swierkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW, Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89:1293-7. [PMID: 12031731 DOI: 10.1016/s0002-9149(02)02329-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
28
|
Swierkosz TA, Valettas N, Herrmann HC. IIb or not IIb: when, how, and which GP IIb/IIIa inhibitor? Catheter Cardiovasc Interv 2001; 52:433-4. [PMID: 11285594 DOI: 10.1002/ccd.1097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T A Swierkosz
- University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
| | | | | |
Collapse
|